Home / Blog / Radiaction raises $12.6M for radiation protection tech

Radiaction raises $12.6M for radiation protection tech

Sep 01, 2023Sep 01, 2023

August 29, 2023 By Sean Whooley

Radiaction Medical announced today that it raised $12.6 million in Series C2 funding and elected Christopher Barys to its board.

U.S. private equity fund InnovaHealth Partners led the Tel Aviv, Israel-based company’s round. Additional unnamed co-investors participated.

Radiaction develops a novel system designed to proactively block radiation from the source. It provides comprehensive, head-to-toe radiation protection for the entire interventional team. Meanwhile, it enables unencumbered patient care, access and service, according to a news release.

Backed by extensive lab testing and real-world validation, the company looks to expand its footprint in the U.S. It’s adding new sites to its user base, providing key support staff to ensure the success of each system installation. The company also looks to develop additional features and grow its clinical publication pipeline to support the technology’s performance.

“This current financing round is a significant step forward, one that enables us to expand our reach further, lead with exceptional customer support, and provide this essential technology to protect those who care for patients,” said Jonathan Yifat, Radiaction CEO.

Barys joins Radiaction’s board with more than 30 years of experience in medical device sales, marketing and business. His experience includes leading growth and innovation within cardiac catheterization and image-guided technologies.

“I am thrilled to be a part of Radiaction’s mission to provide advanced radiation protection to the entire procedural staff,” he said. “Now more than ever, the medical community needs innovative solutions to pressing systemic problems. Radiaction is disrupting the industry for the better. I am looking forward to supporting Radiaction in bringing its radiation reduction solution to every catheterization lab in the U.S. and abroad.”

Yifat called Barys “a tremendous asset” for the strategic composition of Radiaction’s board.

“Chris has a proven track record of market development and growth within the interventional space we aim to serve,” Yifat said. “He brings a keen eye for strategic opportunities and will help guide our company through its next stages of growth.”

Filed Under: Business/Financial News, Funding Roundup, Hospital Care, Imaging, Radiosurgery/Radiation therapy Tagged With: RadiAction Medical